Molecular epidemiology of nalidixic acid resistance in Shigella sonnei isolates

Journal of Bacteriology and Virology

Volumn 35, Issue 1, 2005, Pages 23-30

  Seol, Sung Yong ^a   Do, Yune Kyung ^a   Jeong, Young Sook ^a   Kang, Hee Young ^a   Je, Chul Lee ^a   Yoo, Chul Lee ^a   Dong, Taek Cho ^a   Jung, Tae Hoon ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Epidemiology; gyrA; Nalidixic acid resistance; PFGE; Shigella sonnei

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEUCINE; NALIDIXIC ACID; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM MUTANT; GENE MUTATION; GYRA GENE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; SALMONELLOSIS; SHIGELLA SONNEI;

SHIGELLA SONNEI;

EID: 44849104871     PISSN: 15982467     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Amber JE, Drabu YJ, Blackemore PH, Pinney RJ: Mutator plasmid in a nalidixic acid-resistant strain of Shigella dysenteriae type 1. J Antimicrob Chemother 31: 831-839, 1993.
2. Ashkenazi S, May-Zahav M, Sulkes J, Zilberberg R, Samra Z: Increasing antimicrobial resistance of Shigella isolates in Israel during the period 1984 to 1992. Antimicrobiol Ahents Chemother 39: 819-823, 1995.
3. Ashkenazi S, Levy I, Kazaronovski V, Samra Z: Growing antimicrobial resistance of Shigella isolates. J Clin Microbiol 51: 427-429, 2003.
4. Bennish ML, Salam MA: Rethingking options for the treatment of shigellosis. J Antimicrob Chemother 30: 243-247, 1992.
5. Bhattacharya SK, Bhattacharya MK, Sen PD, Rasily R, Moitra A, Pal SC: Randomized clinical traial of norfloxacin for shigellosis. Am J Trop Med Hyg 456: 683-687, 1991.
6. Bennish ML, Salam MA, Hossain MA, Myaux J, Khan EH, Chakraborty J, Henry E, Ronsmans C: Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infec Dis 14: 1055-1060, 1992.
7. Brown JC, Shanahan PMA, Jasudason MV, Thomson CJ, Amyes SGB: Mutations responsible to reduced susceptibility to 4-quinolones in clinical isolates of multiresistant. Salmonella typhi in India. J Antimicrob Chemothe 37: 891-900, 1996.
8. Chu YW, Houang TSE, Lyon DL, Ling JM: Antimicrobial resistance in Shigella flexneri and Shigella sonnei in Hong Kong, 1986 to 1995. Antinicrob Agents Chemother 42: 440-443, 1998.
9. Corre H, Donnio CPY, Perrin M, Travert MF, Avril JL: Increasing incidence and comparison of nalidixic acid-resistant Salmonella enterica serotype typhimurium isolates from human and animals. J Clin Microbiol 37: 266-269, 1999.
10. DeLappe N, O'Halloran F, Fanning S, Corbett- Feeney G, Cheasty T, Cormican M: Antimicrobial resistance and genetic diversity of Shigella sonnei isolates from western Ireland, an area of low incidence of infection. J Clin Microbiol 41: 1919-1924, 2003.
11. Gautom RK: Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 35: 2977-2980, 1997.
12. Giraud E, Brisabois A, Martel J, Chaslus-Dancla E: Comparative studies of mutations in animal isolates and experimental in vitro and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 43: 2131-2137, 1999.
13. Griggs DJ, Gensberg K, Piddock LVJ: Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from human and animals Antimicrob Agents Chemother 40: 1009-1013, 1996.
14. Hakanen A, Siitonen A, Kotilainen P, Huovinen P: Increasing fluoroquinolone resistance in Salmonella serotypes in Finland during 1995-1997. J Antimicrob Chemother 43: 145-148, 1999.
15. Heisig P, Schedletzky H, Falkenstein-Paul H: Mutation in gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother 37: 696-702, 1993.
16. Hooper DC, Wofson JS, Mozza MA, Ng EY: Genetic and regulations of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother 36: 1151-1154, 1992.
17. Horiuchi S, Inagaki Y, Yamamoto N, Okamura N, Imagawa Y, Nakaya R: Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother 37: 2486-2489, 1993.
18. Liebana E, Clouting C, Cassar CA, Randall LP, Walker RA, Threlfall EJ, Clifton-Hadley FA, Ridley AM, Davies RH: Comparison of gyrA mutations, cyclohexane resistance, and the presence of class I integrons in Salmonella enterica from farm animals in England and Wales. J Clinin Microbio 40: 1481-1486, 2002.
19. Ling JK, Kam M, Lam AW, French GL: Susceptibilities of Hong Kong isolates of multiply resistant Shigella spp to 25 Antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones. Antimicrobiol Agents Chemother 32: 20-23, 1988.
20. Malory B, Schroeter A, Helmuth R: Incidence of quinolone resistance over the period 1986 to 1998 in veterinary Salmonella isolates from Germany. Antimicrob Agents Chemother 43: 2278-2282, 1999.
21. Matsumoto M, Suzuki Y, Sato M, Ishikawa N: Epidemiologic study of Shiigella sonnei from sequential outbreaks and sporadic cases using different typing techniques. Microbiol Immunol 42: 239-264, 1998.
22. Mclver CJ, White PA, Jones LA, Karagiannis T, Harkness J, Marriott D, Rawlinson D: Epidemic strains of Shigella sonnei Biotype g carrying Integrons. J Clin Microbiol 40: 1538-1540, 2002.
23. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, National Committee for Clinical Laboratory Standards. Approved standard M7-A., Villanova, Pa., 2000.
24. Phung LV, Ryo H: Specific gyrA mutation at codon 83 in nalidixic acid-resistant Salmonella enterica serover typhi strains isolated from Vietnamese patients. Antimicrob Agents Chemother 46: 2052-2053, 2002.
25. Reche MP, Rojas AM, Rotger R: gyrA mutation associated with nalidixic acid-resistant Salmonella from wild birds. Antimicrob Agents Chemother 46: 3108-3109, 2002.
26. Reyna F, Huesca M, Gonzalez V, Fuchs LY: Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance. Antimicrob Agents Chemother 39: 1621-1623, 1995.
27. Salam MA, Bennish ML: Therapy of shigellosis: randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 113: 901-907, 1988.
28. Thirunarayana MA, Jesudason MV, John TJ: Resistance of Shigella to nalidixic acid and fluorrinated quinolones. Indian J Med Res 97: 239-241, 1993.
29. Yoshida H, Bogaki M, Nakamura M, Nakamura S: Quinolone resistance-determining region in DNA gyrase gyrA gene of Escherichia coli. Antimicrobiol Agents Chemother 34: 1271-1272, 1990
30. Korean source
31. Korean source
32. Korean source
33. J Bacteriol Virol 32: 23-32, 2002.